Background: Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical.
Methods: We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR).
Results: We observed no significant association between genetic variants and prostate cancer survival.
Conclusions: Common genetic variants with large impact on prostate cancer survival were not observed in this study.
Impact: Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes.
©2015 American Association for Cancer Research.